

Identification of a second bovine amyloidotic spongiform encephalopathy: Molecular similarities with sporadic Creutzfeldt–Jakob disease

Cristina Casalone*[†], Gianluigi Zanusso*[†], Pierluigi Acutis*, Sergio Ferrari[‡], Lorenzo Capucci[§], Fabrizio Tagliavini[¶], Salvatore Monaco[¶], and Maria Caramelli*

*Centro di Referenza Nazionale per le Encefalopatie Animali, Istituto Zooprofilattico Sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna, 148, 10195 Turin, Italy; [†]Department of Neurological and Visual Science, Section of Clinical Neurology, Policlinico G.B. Rossi, Piazzale L.A. Scuro, 10, 37134 Verona, Italy; [‡]Istituto Zooprofilattico Sperimentale della Lombardia ed Emilia Romagna, Via Bianchi, 9, 25124 Brescia, Italy; and [§]Istituto Nazionale Neurologico "Carlo Besta," Via Celoria 11, 20133 Milan, Italy

Edited by Stanley B. Prusiner, University of California, San Francisco, CA, and approved December 23, 2003 (received for review September 9, 2003)

Transmissible spongiform encephalopathies (TSEs), or prion diseases, are mammalian neurodegenerative disorders characterized by a posttranslational conversion and brain accumulation of an insoluble, protease-resistant isoform (PrP^{Sc}) of the host-encoded cellular prion protein (PrP^C). Human and animal TSE agents exist as different phenotypes that can be biochemically differentiated on the basis of the molecular mass of the protease-resistant PrP^{Sc} fragments and the degree of glycosylation. Epidemiological, molecular, and transmission studies strongly suggest that the single strain of agent responsible for bovine spongiform encephalopathy (BSE) has infected humans, causing variant Creutzfeldt–Jakob disease. The unprecedented biological properties of the BSE agent, which circumvents the so-called "species barrier" between cattle and humans and adapts to different mammalian species, has raised considerable concern for human health. To date, it is unknown whether more than one strain might be responsible for cattle TSE or whether the BSE agent undergoes phenotypic variation after natural transmission. Here we provide evidence of a second cattle TSE. The disorder was pathologically characterized by the presence of PrP-immunopositive amyloid plaques, as opposed to the lack of amyloid deposition in typical BSE cases, and by a different pattern of regional distribution and topology of brain PrP^{Sc} accumulation. In addition, Western blot analysis showed a PrP^{Sc} type with predominance of the low molecular mass glycoform and a protease-resistant fragment of lower molecular mass than BSE-PrP^{Sc}. Strikingly, the molecular signature of this previously undescribed bovine PrP^{Sc} was similar to that encountered in a distinct subtype of sporadic Creutzfeldt–Jakob disease.

The transmissible spongiform encephalopathies (TSEs), or prion diseases (1), encompass a group of progressive neurodegenerative disorders, including Creutzfeldt–Jakob disease (CJD) in humans, scrapie in sheep, and bovine spongiform encephalopathy (BSE) (1–4). These disorders are characterized by brain deposition of an insoluble, protease-resistant isoform of the host-encoded cellular prion protein (PrP^C), named PrP^{Sc} (1, 4, 5). In different TSE phenotypes, PrP^{Sc} exhibits disease-specific properties, including distinctive cleavage sites after proteolytic treatment, ratio of glycoforms, and deposition patterns, all features useful in providing a means of strain identification (6–10).

Although not contagious, TSEs are potentially infective, and in humans may present as sporadic, inherited, and acquired diseases. Human-to-human transmission of TSE is well documented and has occurred either through oral or mucocutaneous route of infection, as in kuru (11), or after medical and surgical procedures, as in iatrogenic CJD (12). Recently, animal-to-human transmission has also occurred. Epidemiological (13), experimental transmission (14), and biochemical PrP^{Sc} typing (8) have provided strong evidence that the single prion strain responsible for BSE has infected humans, causing variant CJD

(vCJD), in addition to several animal species. In BSE and BSE-related disorders, including vCJD, the molecular typing of disease-associated PrP^{Sc} shows identical PrP fragment sizes and predominance of the high molecular mass glycoform both in natural hosts and in experimentally inoculated animals. To date, at variance with CJD in humans and scrapie in sheep, only a single strain and a single PrP^{Sc} type have been detected in BSE.

The spreading of the BSE agent across mammalian species barriers has aroused considerable concern for the following reasons: (i) the possible existence of new or previously unrecognized cattle TSE strains, potentially pathogenic for humans; and (ii) the occurrence of phenotypic variation of the BSE strain, with propagation of a new agent encoding distinctive molecular and biological properties.

In Italy, an active surveillance system on BSE in cattle was started in January 2001, and by August 2003 a total of 103 BSE cases had been diagnosed of 1,638,275 statutory tested brainstem samples. Confirmatory positive results have been obtained in all cases by immunohistochemical and Western immunoblot demonstration of disease-specific protease-resistant PrP^{Sc}.

To assess molecular and neuropathological characteristics in Italian BSE cases, we have over the last few months collected whole brains of eight Italian cattle that were PrP^{Sc}-positive in Western immunoblots. In two cattle, older than other affected bovines, the PrP^{Sc} glycoform was clearly different from the BSE-associated PrP^{Sc} molecule, and widespread PrP-amyloid plaques were seen in supratentorial brain regions. Unlike typical BSE, the brainstem was less involved and no PrP deposition was detected in the dorsal nucleus of the vagus nerve. Given the biochemical and pathological similarities with sporadic CJD (sCJD) cases linked to type-2 PrP^{Sc} (9) and methionine/valine (M/V) polymorphism at codon 129 in the prion protein gene (*PRNP*), these findings have prompted ongoing strain typing in inbred mice. Although the present findings dictate caution, here we show that a PrP^{Sc} type associated with sCJD and the previously undescribed bovine PrP^{Sc} show convergent molecular signatures.

Materials and Methods

Tissue Collection and Processing. Whole brains were collected from four Friesian, three Bruna Alpina, and one Piemontese cattle between 5 and 15 years old. All these animals were routinely slaughtered and resulted positive to the statutory rapid TSE test

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: TSE, transmissible spongiform encephalopathy; BSE, bovine spongiform encephalopathy; CJD, Creutzfeldt–Jakob disease; vCJD, variant CJD; sCJD, sporadic CJD; PrP, prion protein; PrP^{Sc}, pathological PrP; BASE, bovine amyloidotic spongiform encephalopathy.

[†]C.C. and G.Z. contributed equally to this work.

[¶]To whom correspondence should be addressed. E-mail: salvatore.monaco@mail.univr.it.

© 2004 by The National Academy of Sciences of the USA

Table 1. Epidemiological, neuropathological, and biochemical findings in examined cattle

Code	Breed	Age, yr	Alleles, octapeptide repeats	Genetic variation	PrP-amyloid plaques	Prevailing PrP ^{Sc} glycoform on Western blot
1088	Piemontese	15	6/6	Wild type	+	Low molecular mass
109655	Bruna Alpina	5	5/7	Wild type	0	High molecular mass
102417	Friesian	9	6/6	Wild type	0	High molecular mass
141387	Bruna Alpina	11	6/7	Codon 70 CAG/CAA, encodes Q/Q	+	Low molecular mass
78437	Bruna Alpina	5	7/7	Codon 70 CAA/CAA, encodes Q/Q	0	High molecular mass
16193	Friesian	5	6/6	Codon 70 CAG/CAA, encodes Q/Q	0	High molecular mass
128204	Friesian	7	6/6	Wild type	0	High molecular mass
72797	Friesian	8	6/6	Codon 70 CAG/CAA, encodes Q/Q	0	High molecular mass

The presence of amyloid plaques was assessed after thioflavin-S staining, PrP immunohistochemistry, and ultrastructural examination. Codon 70 in control cattle and other affected animals was CAG/CAG, encoding Q/Q.

(Prionics, Zurich), which is based on the immunobiochemical detection of bovine PrP^{Sc} in brain samples. Brains were longitudinally cut into two halves; the left hemibrain was frozen and stored at -80°C until biochemical studies, whereas the right part was fixed in 10% buffered formaldehyde solution and dissected in 5-mm-thick sections that were embedded in paraffin after decontamination with 96% formic acid for 1 h. The paraffin-embedded blocks selected for the study included coronal sections at the level of the olfactory bulb, the frontal, parietal, and occipital cortices, the pyriform lobus, hippocampus, striatum, thalamus, brainstem, and sagittal sections through the cerebellum. Brains were also obtained from three routinely slaughtered cattle free of neurological disorders. Tissues from patients with CJD were obtained as described (15).

Bovine PrP Gene Determination. Genomic DNA was isolated from frozen brain tissues by using a QIAamp DNA Mini Kit (Qiagen). PCR amplification of the PrP gene was performed in 50- μl reaction volumes containing 0.5–1 μg of genomic DNA, 25 mM Tris-HCl at pH 8.7, 200 μM each dNTP, 1.5 mM MgCl_2 , 1 unit of *Taq* DNA polymerase, and 1 μM each primer, modified p78 (+) (5'-TAAGTGGGCATATGATGCTC-3') and p9 (-) (5'-CTGGGATTCTCTCTGGTACT-3'), according to previously described procedures (16). Amplification reactions were performed in a Gene Amp PCR system 9700 (Applied Biosystems) for 41 cycles of 1 min at 94°C , 1.5 min at 56°C , and 1 min at 72°C . PrP polymorphisms were detected by DNA sequencing on both strands of the PCR products in an ABI 310 capillary system (Applied Biosystems). To determine the number of copies of the octapeptide repeats, PCR was carried out by using as primers modified p78 (+) and p60 (-) (5'-GATAGTAACGGTCCT-CATAG-3'). PCR amplification products were examined in ethidium bromide-stained 3% agarose gels.

Neuropathology and PrP Immunohistochemistry. Histological sections obtained from each sampled specimen were deparaffinized, rehydrated, and stained with hematoxylin and eosin for evaluation of pathological changes; additional sections were stained with thioflavin-S. For the immunohistochemical study, after rehydration, sections were treated with 96% formic acid for 20 min at room temperature, followed by autoclaving at 121°C for 30 min. After rinsing, sections were incubated overnight at 4°C with anti-PrP monoclonal antibody F99/97.6.1 (17) diluted to 1/1,000. Subsequent antibody detection was carried out by using a biotinylated goat anti-mouse secondary antibody diluted to 1/200 for 20 min (Vector Laboratories, Burlingame, CA) at room temperature, followed by the avidin-biotin-peroxidase complex (Vectastain ABC kit, Vector Laboratories) according to manufacturer's protocol. Immunoreactivity was visualized by using 3,3'-diaminobenzidine as chromogen.

For electron microscopic study, formalin-fixed specimens of brain tissues were extensively washed in PBS, fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, and postfixed with 2% osmium tetroxide for 2 h. After dehydration in graded acetone solutions, tissues were embedded in Spurr's resin. Subsequently, the sections were prepared for electron microscopy and observed with a Zeiss EM 109 electron microscope.

Immunoblot Analysis. From each central nervous system sample, 100 mg of tissue was homogenized in 9 vol of lysis buffer (100 mM sodium chloride/10 mM EDTA/0.5% Nonidet P-40/0.5% sodium deoxycholate/10 mM Tris-HCl, pH 7.4) and digested with 50 $\mu\text{g}/\text{ml}$ proteinase K (Boehringer Mannheim) for 1 h at 37°C . Digestion was blocked by the addition of phenylmethylsulfonyl fluoride at 2 mM. For deglycosylation, proteinase K-digested samples were deglycosylated with recombinant peptide N-glycosidase F (PNGase F) according to the supplier's instructions (Boehringer Mannheim). Samples, equivalent to 400 μg of wet tissue, were resolved by electrophoresis on 13% polyacrylamide gels and then transferred onto PVDF membrane (Immobilon P; Millipore) for 2 h at 60 V. Membranes were blocked with 1% nonfat dry milk in TBST (10 mM Tris-HCl/150 mM sodium chloride/0.1% Tween 20, pH 7.5) for 1 h at 37°C and incubated overnight at 4°C with anti-PrP monoclonal antibody 6H4 (Prionics) diluted to 1/5,000. Blots were developed by using the Amersham Pharmacia enhanced chemiluminescence (ECL) system, as described by the supplier and visualized on an autoradiography film. Films were scanned by using a densitometer (GS-710; Bio-Rad). The relative amounts of PrP^{Sc} distribution were calculated as previously described (18).

Results

Genetic Analysis. In four cattle a silent mutation at codon 70 (CAG \rightarrow CAA) was found. As to the number of octapeptide repeats, a common cattle polymorphism, five animals were homozygous for PrP genotype with six copies and one for seven copies, whereas two Bruna Alpina cattle were heterozygous, having five/seven and six/seven repeats, respectively. Genetic, pathological and biochemical findings are summarized in Table 1.

Neuropathology and Immunohistochemistry. Although the presence of early autolysis precluded an accurate pathological assessment in some brain areas, in all animals spongiosis was not consistently found in the brainstem, at the level of the obex or in more rostral areas. The frontal, parietal, and occipital cortices were apparently spared, and no vacuolation was detected in the olfactory bulb, pyriform cortex, and hippocampus. Mild spongiform changes of the neuropil were observed only in two Friesian cattle at the level of the thalamus. However, after PrP immunohisto-




Fig. 2. PrP-positive amyloid plaques in group 2 animals. PrP-immunostaining of the pyriform cortex from group 2 cattle, showing the presence of kuru-like amyloid plaques (a and b, $\times 450$). At ultrastructural examination amyloid deposits are composed of aggregates and bundles of unbranched fibrils (c, $\times 12,550$; d, $\times 60,000$).

plaques were seen in the thalamus (Fig. 1d), subcortical white matter and deeper layers of cerebral cortex (Fig. 1f), and olfactory bulb (Fig. 1h). Finally, the molecular layer of the cerebellum exhibited PrP deposits of the glial type in group 1, whereas some amyloid plaques were observed in group 2.

Biochemical Characterization and Regional Distribution of PrP^{Sc}.

Western immunoblots of proteinase K-treated brain homogenates, obtained from different cortical and subcortical regions of group 1 and group 2 animals, showed the presence of two distinct PrP^{Sc} types, which were distinguishable on the basis of the molecular mass of their unglycosylated fragments and the ratio of differently glycosylated forms. The typical molecular “BSE signature,” characterized by overrepresentation of the high molecular mass glycoform, was detected in group 1 animals (Fig. 3a, odd lanes). In contrast, the Piemontese and Bruna Alpina cattle (group 2) showed a predominance of the low molecular mass glycoform and a protease-resistant fragment with a faster electrophoretic mobility (Fig. 3a, even lanes).

In prion diseases, distinct PrP^{Sc} types usually result in different patterns of deposition and brain regional distribution of the abnormal protein. In group 1 animals, the highest amounts of PrP^{Sc} were recovered, as expected, in the brainstem, hypothalamus, and thalamus, and very low PrP^{Sc} levels were found in the olfactory bulb and pyriform cortex (Fig. 3b). Conversely, the distribution of PrP^{Sc} in group 2 cattle was more widespread than in typical BSE cases, and the largest amounts of PrP^{Sc} were detected in the thalamus, olfactory bulb, hippocampus, and olfactory cortex, whereas lower PrP^{Sc} levels were recovered in the brainstem (Fig. 3c). On the basis of the neuropathological phenotype and the PrP^{Sc} distribution and glycoform, group 2 cattle were reminiscent of the sCJD phenotype seen in subjects with M/V at *PRNP* codon 129 and type 2 PrP^{Sc} (M/V2) (9, 19). Therefore, we compared proteinase K-treated brain homogenates from group 1 and group 2 cattle with sCJD with different




Fig. 3. Biochemical analysis and regional distribution of PrP^{Sc} in group 1 and group 2 cattle. (a) Immunoblot with 6H4 monoclonal antibody of proteinase K-treated brain homogenates from the thalamus of group 1 (odd lanes) and group 2 animals (even lanes), before (lanes 1–4) and after (lanes 5–8) enzymatic deglycosylation. (b and c) Regional distribution of brain PrP^{Sc} in group 1 (b) and group 2 (c) cattle; values of PrP^{Sc} are reported below each gel as the percentage of the highest value obtained. Molecular size markers are shown on the right as $M_r \times 10^{-3}$.

molecular types of PrP^{Sc}, either homozygous or heterozygous at *PRNP* codon 129. Remarkably, the PrP^{Sc} type detected in TSE-affected cattle from group 2 had fragment size (Fig. 4a) and glycoform ratios (Fig. 4b) similar to a PrP^{Sc} type encountered in sCJD M/V2 (9, 19).

Discussion

In natural and experimental TSEs, PrP^{Sc} deposition represents an early event that occurs weeks to months before the development of spongiform changes (20, 21). As a consequence, the detection of PrP^{Sc} by Western immunoblot provides a unique opportunity in the diagnosis of BSE early in the incubation period and, therefore, in presymptomatic animals. The identification of the present cattle by postmortem biochemical tests, in the absence of clear neurological involvement, suggests that the disorder was detected at early stages, and this may also explain the lack of widespread vacuolar changes.

Previous pathological studies in clinically suspect cases of BSE in Great Britain have provided evidence for a uniform pattern in the severity and distribution of vacuolar lesions in affected animals, with medulla oblongata nuclei being the most involved (22). While confirming that the BSE epidemic has been sustained by a single agent, these studies have assessed the validity of statutory criteria for the diagnosis of BSE, which is currently based on both histopathological and immunobiochemical exam-




Fig. 4. Electrophoretic analysis of PrP^{Sc} in cattle TSE and sCJD. (a) Western blot detection of PrP^{Sc} in brains of group 1 animals (lanes 1 and 5); subject with sCJD and type 1 PrP^{Sc}, methionine/methionine at codon 129 (lane 2); subject with sCJD and type 2 PrP^{Sc}, methionine/valine at codon 129 (lane 3); and group 2 cattle (lane 4). (b) Relative proportions of the three PrP^{Sc} glycoforms in group 1 and group 2 cattle compared with glycoform profiles obtained in nine sCJD patients, methionine/valine at codon 129 and with type 2 PrP^{Sc}. Mean \pm standard deviation is shown. Upper band, diglycosylated form; middle band, monoglycosylated form; and lower band, unglycosylated form.

ination of the medulla. However, the prevailing involvement of cortical regions in the cattle with amyloid deposition suggests that postmortem brain sampling should not be limited to the obex. In addition, a careful analysis of PrP^{Sc} glycoform profiles at the confirmatory Western immunoblot may provide a molecular means of identifying atypical cases of bovine TSE.

Bovine Amyloidotic Spongiform Encephalopathy (BASE): A Second Bovine TSE. The present findings show that a previously undescribed pathological and immunohistochemical phenotype, associated with cattle TSE, is related to the presence of a PrP^{Sc} type with biochemical properties, including the gel mobility of the protease-resistant fragment and glycoform ratios, different from those encountered in cattle BSE. Brain deposition of this pathological isoform of cattle PrP correlates with the formation of PrP-amyloid plaques, as opposed to typical BSE cases. Although in several natural and experimental recipients of the BSE agent, including humans (13), neuropathological changes are characterized by the presence of PrP-positive amyloid deposits with surrounding vacuolation, cattle BSE is not associated with PrP-amyloid plaque formation. On the basis of the above features, we propose to name the disease described here BASE. Although observed in only two cattle, the BASE phenotype could be more common than expected. In previous studies, amyloid congophilic plaques were found in 1 of 20 BSE cases examined systematically for amyloid (23), and it was reported that focal cerebral amyloidosis is present in a small proportion of BSE cases (24). Although no biochemical analysis of PrP^{Sc} glycoform is available for these animals with “atypical BSE phenotype,” our present results underscore the importance of performing a strain-typing in bovine TSE with amyloid deposition.

In sCJD, the neuropathological phenotype largely correlates with the molecular type of PrP^{Sc} and distinct polymorphic sites

of PRNP (9, 19). This is in contrast with the situation in cattle, where different genotypes have been reported based on the variable numbers of octapeptide repeats in each allele, but no evidence for single-codon polymorphisms in the PrP gene has been established (25, 26). Because the present animals shared a similar genetic background and breed, differences in disease phenotypes between cattle with BSE and BASE can be tentatively related only to distinct PrP^{Sc} types or alternative routes of infection and spread of prion pathology. Accordingly, the lack of involvement of the motor dorsal nucleus of the vagus and the slight involvement of the brainstem in BASE, suggests a route for spreading of the agent other than the alimentary tract. Therefore, unless the BASE agent propagates throughout the olfactory pathway or other peripheral routes, it is possible that this disorder represents a sporadic form of cattle TSE, which would also explain the difference in ages between the two groups of affected animals.

Phenotypic Similarities Between BASE and sCJD. The transmissibility of CJD brains was initially demonstrated in primates (27), and classification of atypical cases as CJD was based on this property (28). To date, no systematic studies of strain typing in sCJD have been provided, and classification of different subtypes is based on clinical, neuropathological, and molecular features (the polymorphic PRNP codon 129 and the PrP^{Sc} glycoform) (8, 9, 15, 19). The importance of molecular PrP^{Sc} characterization in assessing the identity of TSE strains is underscored by several studies, showing that the stability of given disease-specific PrP^{Sc} types is maintained upon experimental propagation of sCJD, familial CJD, and vCJD isolates in transgenic PrP-humanized mice (8, 29). Similarly, biochemical properties of BSE- and vCJD-associated PrP^{Sc} molecules remain stable after passage to mice expressing bovine PrP (30). Recently, however, it has been reported that PrP-humanized mice inoculated with BSE tissues may also propagate a distinctive PrP^{Sc} type, with a “monoglycosylated-dominant” pattern and electrophoretic mobility of the unglycosylated fragment slower than that of vCJD and BSE (31). Strikingly, this PrP^{Sc} type shares its molecular properties with the a PrP^{Sc} molecule found in classical sCJD. This observation is at variance with the PrP^{Sc} type found in M/V2 sCJD cases and in cattle BASE, showing a monoglycosylated-dominant pattern but faster electrophoretic mobility of the protease-resistant fragment as compared with BSE. In addition to molecular properties of PrP^{Sc}, BASE and M/V2 sCJD share a distinctive pattern of intracerebral PrP deposition, which occurs as plaque-like and amyloid-kuru plaques. Differences were, however, observed in the regional distribution of PrP^{Sc}. While in M/V2 sCJD cases the largest amounts of PrP^{Sc} were detected in the cerebellum, brainstem, and striatum, in cattle BASE these areas were less involved and the highest levels of PrP^{Sc} were recovered from the thalamus and olfactory regions.

In conclusion, decoding the biochemical PrP^{Sc} signature of individual human and animal TSE strains may allow the identification of potential risk factors for human disorders with unknown etiology, such as sCJD. However, although BASE and sCJD share several characteristics, caution is dictated in assessing a link between conditions affecting two different mammalian species, based on convergent biochemical properties of disease-associated PrP^{Sc} types. Strains of TSE agents may be better characterized upon passage to transgenic mice. In the interim until this is accomplished, our present findings suggest a strict epidemiological surveillance of cattle TSE and sCJD based on molecular criteria.

We are grateful to Giuseppe Ru (Centro di Referenza Nazionale per le Encefalopatie Animali, Istituto Zooprofilattico Sperimentale di Torino) for the provision of surveillance data. We also thank Diana Bazan for preparing material for transmission electron microscopy, and Ines

Crescio, Cristiano Corona, Cristiano Longo, Michele Fiorini, Alessia Farinazzo, and Matteo Gelati for technical assistance. This work was supported by a grant from the Italian Ministry of Health (IZS PLV

004/01 to M.C. and S.M.), a grant from Fondazione Cariverona (2002-Malattie neurodegenerative to S.M.), and in part by the Italian Ministry of Health (RF 2001.96 to F.T.).

1. Prusiner, S. B. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 13363–13383.
2. Collinge, J. (2001) *Annu. Rev. Neurosci.* **24**, 519–550.
3. Parchi, P. & Gambetti, P. (1995) *Curr. Opin. Neurol.* **8**, 286–293.
4. Brown, P., Goldfarb, L. G. & Gajdusek, D. C. (1991) *Lancet* **337**, 1019–1022.
5. Prusiner, S. B. (1992) *Biochemistry* **31**, 12277–12288.
6. Bessen, R. A. & Marsh, R. F. (1992) *J. Virol.* **66**, 2096–2101.
7. Bessen, R. A. & Marsh, R. F. (1994) *J. Virol.* **68**, 7859–7868.
8. Collinge, J., Sidle, K. C. L., Meads, J., Ironside, J. & Hill, A. F. (1996) *Nature* **383**, 685–690.
9. Parchi, P., Castellani, R., Capellari, S., Ghetti, B., Young, K., Chen, S. G., Farlow, M., Dickson, D. W., Sima, A., Trojanowski, J. Q., *et al.* (1996) *Ann. Neurol.* **39**, 767–778.
10. Hill, A. F., Sidle, K. C. L., Joiner, S., Keyes, P., Martin, T. C., Dawson, M. & Collinge, J. (1998) *Neurosci. Lett.* **255**, 159–162.
11. Gajdusek, D. C. (1977) *Science* **197**, 943–960.
12. Brown, P., Preece, M. A. & Will, R. G. (1992) *Lancet* **340**, 24–27.
13. Will, R. G., Ironside, J. W., Zeidler, M., Cousens, S. N., Estibeiro, K., Alperovitch, A., Poser, S., Pocchiari, M., Hofman, A. & Smith, P. G. (1996) *Lancet* **347**, 921–925.
14. Bruce, M. E., Will, R. G., Ironside, J. W., McConnell, I., Drummond, D., Suttle, A., McCardle, L., Chree, A., Hope, J., Birkett, C., *et al.* (1997) *Nature* **389**, 498–501.
15. Zanusso, G., Farinazzo, A., Fiorini, M., Gelati, M., Castagna, A., Rigetti, P. G., Rizzuto, N. & Monaco, S. (2001) *J. Biol. Chem.* **276**, 40377–40380.
16. Belt, B. G. M., Muileman, I. H., Schreuder, B. E. C., Bos-de Ruijter, J., Gielkens, A. L. J., Smits, M. A. (1995) *J. Gen. Virol.* **76**, 509–517.
17. O'Rourke, K. I., Baszler, T. V., Besser, T. E., Miller, J. M., Cutlip, R. C., Wells, G. A., Ryder, S. J., Parish, S. M., Hamir, A. N., Cockett, N. E., *et al.* (2000) *J. Clin. Microbiol.* **38**, 3254–3259.
18. Zanusso, G., Ferrari, S., Cardone, F., Zampieri, P., Gelati, M., Fiorini, M., Farinazzo, A., Gardiman, M., Cavallaro, T., Bentivoglio, M., *et al.* (2003) *N. Engl. J. Med.* **348**, 711–719.
19. Parchi, P., Giese, A., Capellari, S., Brown, P., Schulz-Schaeffer, W., Windl, O., Zerr, I., Budka, H., Kopp, N., Piccardo, P., *et al.* (1999) *Ann. Neurol.* **46**, 224–233.
20. Castellani, R., Parchi, P., Stahl, J., Capellari, S., Cohen, M. & Gambetti, P. (1996) *Neurology* **46**, 1690–1693.
21. DeArmond, S. J. & Prusiner, S. B. (1995) *Am. J. Pathol.* **146**, 785–811.
22. Simmons, M. M., Harris, P., Jeffrey, M., Meek, S. C., Blamire, I. W. H. & Wells, G. A. H. (1996) *Vet. Rec.* **138**, 175–177.
23. Wells, G. A. H. & Wilesmith, J. W. (1995) *Brain Pathol.* **5**, 91–103 .
24. Wells, G. A. H., Wilesmith, J. W., McGill, I. S. (1991) *Brain Pathol.* **1**, 69–78.
25. Goldmann, W., Hunter, N., Martin, T., Dawson, M. & Hope, J. (1991) *J. Gen. Virol.* **72**, 201–204.
26. Hunter, N., Goldmann, W., Smith, G. & Hope, J. (1994) *Vet. Rec.* **135**, 400–403.
27. Gibbs, C. J., Jr., Gajdusek, D. C., Asher, D. M., Alpers, M. P., Beck, E., Daniel, P. M. & Matthews, W. B. (1968) *Science* **161**, 388–389.
28. Brown, P., Rodgers-Johnson, P., Cathala, F., Gibbs, C. J., Jr. & Gajdusek, D. C. (1984) *Ann. Neurol.* **16**, 295–304.
29. Korth, C., Kaneko, K., Groth, D., Heye, N., Telling, G., Mastrianni, J., Parchi, P., Gambetti, P., Will, R., Ironside, J., *et al.* (2003) *Proc. Natl. Acad. Sci. USA* **100**, 4784–4789.
30. Scott, M. R., Will, R., Ironside, J., Nguyen, H.-O. B., Tremblay, P., DeArmond, S. J. & Prusiner, S. B. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 15137–15142.
31. Asante, E. A., Linehan, J. M., Debruslais, M., Joiner, S., Gowland, I., Wood, A. L., Welch, J., Hill, A. F., Lloyd, S. E., Wadsworth, J. D. F. & Collinge, J. (2002) *EMBO J.* **21**, 6358–6366.